Application and clinical impact of the RESIST-4 O.K.N.V. rapid diagnostic test for carbapenemase detection in blood cultures and clinical samples

Eur J Clin Microbiol Infect Dis. 2021 Feb;40(2):423-428. doi: 10.1007/s10096-020-04021-4. Epub 2020 Sep 7.

Abstract

Invasive infections caused by carbapenemase-producing bacteria are associated with excess mortality. We applied a rapid diagnostic test (RDT) on clinical samples with an elevated likelihood of carbapenemase-producing bacteria and documented its impact on antibiotic treatment decisions. Among 38 patients, twelve tested positive for infections caused by carbapenemase-producing bacteria (31.6%), mainly in blood cultures. KPC (n = 10) was more frequent than OXA-48 (n = 2). RDT-based carbapenemase detection led to a treatment modification to ceftazidime/avibactam-containing regimens in all patients before detailed antibiotic testing results became available. Eleven patients (92%) survived the acute infection, whereas one patient with a ceftazidime/avibactam- and colistin-resistant OXA-48-positive isolate died.

Keywords: Antibiotics; Clinical microbiology; Diagnostic stewardship; Enterobacterales; Escherichia coli; Klebsiella pneumoniae; Treatment.

MeSH terms

  • Aged
  • Bacterial Proteins
  • Blood Culture / methods*
  • Diagnostic Tests, Routine / methods*
  • Enterobacteriaceae / enzymology
  • Enterobacteriaceae / isolation & purification*
  • Enterobacteriaceae Infections / diagnosis*
  • Female
  • Humans
  • Male
  • Middle Aged
  • Point-of-Care Testing*
  • beta-Lactamases

Substances

  • Bacterial Proteins
  • beta-Lactamases
  • carbapenemase